Carmine Stengone
Chief Executive Officer chez CONTINEUM THERAPEUTICS, INC.
Fortune : 178 825 $ au 31/03/2024
Profil
Carmine Stengone is the founder of Afraxis, Inc., which was founded in 2010.
He held the title of President & Chief Executive Officer from 2013 to 2014.
Mr. Stengone's current job(s) include Chairman, President & Chief Executive Officer at Contineum Therapeutics, Inc. since 2018, Independent Director at Kiora Pharmaceuticals, Inc. since 2023, and Director at Avelas Biosciences, Inc. since 2012.
Mr. Stengone's former job(s) include Senior Director-Business Development at Phenomix Corp.
from 2006 to 2010, Senior Manager-Strategic Marketing at Anadys Pharmaceuticals, Inc. from 2004 to 2006, Principal at Johnson & Johnson Pharmaceutical Research & Development LLC from 2003 to 2004, and Senior Vice President-Business Development at COI Pharmaceuticals, Inc. from 2013 to 2018.
Mr. Stengone's education history includes a graduate degree from Duke University in 1999, an undergraduate degree from Wake Forest University in 1997, and an MBA from Johnson Graduate School of Management in 2003.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/04/2024 | 11 612 ( 0,05% ) | 178 825 $ | 31/03/2024 |
Postes actifs de Carmine Stengone
| Sociétés | Poste | Début |
|---|---|---|
| CONTINEUM THERAPEUTICS, INC. | Chief Executive Officer | 01/10/2018 |
| KIORA PHARMACEUTICALS, INC. | Director/Board Member | 01/08/2023 |
Avelas Biosciences, Inc.
 Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Director/Board Member | 07/02/2014 |
Anciens postes connus de Carmine Stengone
| Sociétés | Poste | Fin |
|---|---|---|
COI Pharmaceuticals, Inc.
 COI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology COI Pharmaceuticals, Inc. provides life science investors. It offers research and development infrastructure and industry mentors to the portfolio companies of Avalon Ventures. The company was founded in 2013 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | 01/10/2018 |
Phenomix Corp.
 Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Corporate Officer/Principal | 28/10/2010 |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Sales & Marketing | 01/01/2006 |
Johnson & Johnson Pharmaceutical Research & Development LLC
 Johnson & Johnson Pharmaceutical Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ. | Corporate Officer/Principal | 01/01/2004 |
Afraxis, Inc.
 Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Founder | - |
Formation de Carmine Stengone
| Duke University | Graduate Degree |
| Wake Forest University | Undergraduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KIORA PHARMACEUTICALS, INC. | Health Technology |
| CONTINEUM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Anadys Pharmaceuticals, Inc.
Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Health Technology |
Afraxis, Inc.
Afraxis, Inc. BiotechnologyHealth Technology Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA. | Health Technology |
Johnson & Johnson Pharmaceutical Research & Development LLC
Johnson & Johnson Pharmaceutical Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ. | Commercial Services |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Health Services |
COI Pharmaceuticals, Inc.
COI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology COI Pharmaceuticals, Inc. provides life science investors. It offers research and development infrastructure and industry mentors to the portfolio companies of Avalon Ventures. The company was founded in 2013 and is headquartered in La Jolla, CA. | Health Technology |
